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1. SINOPSI 
L’ús del Busulfan com a agent quimioteràpic ha anat desapareixent a mesura que 
noves i millors alternatives terapèutiques han sortit al mercat. Actualment s’utilitza en 
algunes malalties mieloproliferatives i en l’acondicionament previ al Transplantament de 
Progenitors Hematopoètics. Durant el desenvolupament d’aquest projecte hem utilitzat 
dades de 98 pacients prenent Busulfan via oral (1mg/Kg/6h) conjuntament amb altre 
medicació concomitant en l’esmentat acondicionament per desenvolupar un model 
farmacocinètic poblacional per predir concentracions plasmàtiques en pacients.  
Es va obtenir un model monocompartimental que ajustava la seva variabilitat 
interindividual (IIV) per l’Aclariment (CL/F) amb un Valor Típic de 11.0 L/h i pel Volum de 
distribució (V/F) amb un Valor Típic de 42.7 L. Ambdós paràmetres ajustaven millor les 
dades utilitzant la covariable “Pes Corporal Ideal Ajustat” per explicar part de l’error 
residual. El model definitiu va passar dos processos de validació interna i serà utilitzat 
properament en la unitat de farmacocinètica clínica de l’Institut Català d’Oncologia amb 
la intenció de poder detectar aquells pacients que arribarien a concentracions tòxiques 
i evitar efectes adversos derivats del seu ús. 
SYNOPSIS 
The applications of Busulfan as a chemotherapeutic agent has been disappearing 
over the years as better therapeutic alternatives have been released. Nowadays it is 
mainly used for some myeloproliferative diseases and the conditioning process previous 
to Hematopoietic Stem Cell Transplantation. During this project, data was collected from 
98 patients taking Busulfan for the aforementioned conditioning, which were further used 
to develop a population pharmacokinetic model aiming to predict plasma concentrations 
of the drug in patients.  
A one-compartment model best described the data, which adjusted its interindividual 
variability for clearance (CL/F) with a Typical Value of 11.0 L/h, and for the distribution 
volume (V/F) with a Typical Value of 42.7 L. Both parameters showed a better fit to the 
data by the application of the Adjusted Ideal Body Weight covariate to explain the 
residual error. The final model went through two internal validation processes and will be 
used henceforth in the clinical pharmacokinetic unit of the Catalan Oncology Institute 
targeting those patients with potential to achieve toxic concentrations and avoid adverse 
events derived from its use. 
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2. FIELD JUSTIFICATION 
This project rests upon three pillars. The main field of study is Biopharmacy & 
Pharmacokinetics. The whole project is mainly focused on the development of a 
population model of Busulfan, so a deep research and insight had to be acquired to 
understand its concepts and being able to analyze the output information provided by 
the model-building software with a critical point of view. Pharmacokinetics was also basic 
to learn the behavior of the drug regarding its absorption, distribution, metabolization, 
and excretion in the human body. 
The secondary fields were for one: Physiology & Physiopathology which was crucial 
to understand the cellular bases of myeloproliferative diseases, specially blood cancers 
(leukemias, lymphomas, myelomas, myelodysplastic syndromes, etc.) and the 
implications, and consequences derived from all stages of the Hematopoietic Stem Cell 
Transplantation (HSCT). Pharmacology & Therapeutics knowledge was required to 
interpret the role of Busulfan and other concomitant medication in the conditioning 
procedure previous to HSCT, and the immunosuppressive therapy after the transplant. 
Furthermore, both disciplines allowed a better comprehension of the potential side 
effects of the studied drugs, and its optimal therapeutic range. 
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3. INTRODUCTION 
3.1. Busulfan  
Busulfan is a bifunctional alkylating agent chemically named 1,4-butanediol 
dimethanesulphonate. It is not a structural analog of nitrogen mustards. The ATC 
classification given by AEMPS (“Agencia Española de Medicamentos y Productos 
Sanitarios”) is L01AB01, inside the alkylsulphonates alkylating drugs according to the 
Spanish regulation. Nowadays, there are two available presentations of the drug: an oral 
2 mg tablet or a powder for infusion. Busulfan was developed as a cancer treatment by 
Glaxo-Smith-Kline in 1959. It is a small lipophilic molecule (MW: 246.29 g/mol;             
LogP = -0.5; Solubility: 69 mg/mL) which presents as a white, needle-like crystal. 
 
Figure 1.1. Busulfan chemical structure. 
3.1.1. ADME 
Busulfan has a variable permeability due to its low solubility in water. When given 
orally, the assimilated fraction is around 0.8 but it presents a high inter-individual 
variability due to age, weight, and time of dosage.(1)(2) Hassan et.al.(3) and Schuler 
et.al. (4)performed a comparison between intravenous and oral doses of busulfan and 
estimated an 80%(SD: 19, range 22-120%) bioavailability in infants and adults and a 
70% (range 44-94) in adults only (23-54 years). Due to its lipophilic nature, busulfan 
reaches the cerebrospinal fluid at a concentration equal to those in plasma by crossing 
the Blood-Brain Barrier (BBB). Even though it has a neglectable reversible protein 
binding (about 7%), it has a relevant irreversible bonding to albumin (about 30%).(5) 
The drug is not typically excreted unaltered in urine (only 1%) as a result of extensive 
metabolization in liver by glutathione S-transferase and spontaneous conjugation to 
glutathione. About 30% of the metabolite is then excreted in urine, and the rest is largely 
oxidized in the liver although not excreted in feces.(12) The main pharmacokinetic 
parameters have been widely studied over the years since its approval. The available 
literature has been reviewed and summarized in Table1.2.1 and 1.2.2. 
Table 1.2.1. Integrated busulfan oral PK parameters 
from literature.(3,13–18) 
 
 
 
 
Table 1.2.2. Integrated busulfan intravenous PK  
 parameters from literature.(4,6–11)  
IV Units Range SD 
AUC/D mg·h/D 5.99 - 9.45 1.6 
CL L/h 8.05 - 11.44 2.14 
t1/2 h 2.44 - 3.38 0.26 
V L/Kg 0.55 - 0.57 0.02 
ORAL Units Range SD 
AUC mg·h/mL 5.90 - 8.26 0.94 
CL/F L/h 10.5 - 12.8 1.54 
t1/2  h 2.33 – 3.39 0.26 
V/F  L/Kg 0.56 – 0.66 0.04 
Ka  h-1 0.02- 0.055 1.02 
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Albeit it is considered residual, some studies performed in rats suggest a role of the 
microsomal fraction in the metabolism of busulfan at high doses, causing an enhanced 
activity of N-nitrosodimethylamine demethylase (NDMA-demethylase), an enzyme 
largely related to human CYP2A6 and CYP2E1.(19–22) 
3.1.2. Pre-existing Pharmacokinetic Models of Busulfan 
Since its approval, some Pharmacokinetic Models have been developed. These 
models vary in the number of patients and the location where the study was performed. 
Six models have been constructed based on data from intravenous busulfan, an easier 
approximation in view of the erratic bioavailability of oral busulfan. Oral busulfan models 
are therefore sparse but three could be reviewed. 
The results of the PK parameters obtained in the preexisting models are summarized 
in Table 1.2.1. and 1.2.2. 
Table 1.2.3.Comparation of population PK parameters of Busulfan models in 
literature.(23–28)  
Intravenous N Nº. CMT TVCL (L/h) TVV1(L) TVV2 (L) TVQ (L/h) 
McCune J et.al 1610 2 12.4 13.9 29.9 135.2 
Salinger D et.al 37 1  12.5*  50.6* - - 
Wang Y et.al. 207 1 12.9 48.3 - - 
Choi B et.al 36 1 11.0 42.4 - - 
Kawazoe A et.al. 54 2 11.8 13.0 31.9 88.1 
Wu X et.al. 53 1 11.8 48.2 - - 
Median - - 12.0 46.3 111.6 
SD - - 0.6 2.8 23.5 
 *Calculated assuming a 70 kg subject. Original data was normalized by weight. 
 
Table 1.2.4. Comparation of population PK parameters from oral Busulfan models 
in literature. (29–31) 
 *Calculated assuming a 70 kg subject. Original data was normalized by weight. 
 
We observe that estimated parameters are very similar in both oral and intravenous 
(IV) models when oral parameters were normalized by the absorbed fraction. 
3.1.3. Clinical Uses 
The two methanesulphonate groups of busulfan are highly reactive. They are mostly 
hydrolyzed by water in the internal fluid releasing methanesulphonyl cations, but also 
can cross-react with proteins (that act as a nucleophile) due to the electrophilic properties 
of the α-carbons of the drug. Then, the generated carbonium anions can alkylate DNA 
and have a fatal effect in cells.(12) 
Nowadays its use is restricted to a few myeloproliferative diseases owing to its 
myelosuppressive effects. For instance, it is used in Polycythemia Vera as a second-line 
drug for hydroxyurea refractory or intolerant, showing a broader activity versus this 
myeloproliferative disease than α-peg-interferon and ruxolutinib, and a long-term 
hematological control or even remission. It has even been compared to hydroxyurea, 
Oral  N Nº. CMT TVCL/F (L/h) TVV/F (L) TVKa (h-1) Tlag (h) 
De Castro F. et.al.  29 2 12.3 48.8 3.98 0.20 
Hadjibabaie M. et.al.  30 2 13.4 42.6 - - 
Takamatsu Y. et.al.  71 2 10.7* 48.6* 2.93 - 
Median  - - 12.1 46.6 3.45 - 
SD  - - 1.1 2.8 0.52 - 
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and large safety and clinical data has been collected from busulfan as a first-line 
therapy.(32–37) 
Busulfan was the first treatment of Chronic Myeloid Leukemia (CML), improving the  
effectivity of concomitant radiotherapy and the quality of life, but not increasing the 
overall survival of patients.(38) Since 1983 this drug is not commonly used for CML since 
it has been long substituted by α-interferon, TK inhibitors (imatinib, dasatinib, and 
nilotinib), and Hematopoietic Stem Cell Transplantation (HSCT).(39,40) 
Hematopoietic Stem Cell Transplantation (HSCT) is used as therapy for many 
hematological diseases either malignant or not. This therapeutic approach has been 
improved over the past decades, enhancing its success rate and reducing its 
mortality.(41)  
According to the American Society for Bone Marrow Transplantation, HSCT 
(autologous and/or allogenic) is Standard of Care in adults for the following diseases: 
Table 1.2.5. Indications for HSCT as Standard of Care in malignant and non-
malignant diseases. (42,43) 
Malignant diseases  
     Acute Myeloid Leukemia     Diffuse large B cell Lymphoma** 
     Acute Lymphoblastic Leukemia     Follicular Lymphoma 
     Chronic Myeloid Leukemia     Mantle cell Lymphoma 
     Myelodysplastic syndromes     Lymphoplasmatic Lymphoma** 
     T-cell Lymphoma     Cutaneous T cell Lymphoma 
     Chronic Lymphocytic Leukemia  
     Burkitt’s Lymphoma  
     Hodgkin Lymphoma** Non-malignant diseases 
     Anaplastic Large Cell Lymphoma**      Aplastic anemia 
     Myelofibrosis and myeloproliferative      Sickle cell disease 
     Plasma Cell disorders      Thalassemia 
     Acute Promyelocytic Leukemia**      Polycythemia Vera 
     Some solid tumors*      Other rare indications 
*Only autologous HSCT for Germ Cell Tumor, and Ewing’s Sarcoma 
**Except after the first complete response (CR1).    
 
Before transplantation, there is usually a conditioning regimen performed in the host, 
that may vary according to their characteristics or the established medical procedures in 
the hospital. The main three types of conditioning therapies were named in 2006 by the 
Center for International Blood and Marrow Transplant Research: 
— Myeloablative or high-dose conditioning (HDC) is usually performed in adult 
patients with hematological malignancies due to its immunosuppressive activity 
to better tolerate the donor’s hematopoietic progenitors, and antineoplastic 
properties reducing the malignancy burden. It is carried out with alkylating agents, 
or total body irradiation (TBI) plus alkylating agents. High dose busulfan is usually 
used due to its effect in either dividing or non-dividing cells although it must be 
given concomitantly with other agents such as cyclophosphamide, Thiotepa, 
thymoglobulin, or fludarabine, since it has a limited effect in mature lymphocytes. 
The standard doses of busulfan are 1 mg/kg (oral) or 0.8 mg/kg (IV) every 6 hours 
for 4 days.(44–46) 
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— Non-myeloablative (NMC) and reduced-intensity chemotherapy (RIC) 
conditioning regimens produce mild cytopenia and makes them suitable for older, 
pediatric patients that are not candidates for high-dose regimens. Initially a donor-
host graft chimerism is produced, and eventually evolves into full donor graft in 
the following days (in RIC) or months (in NMC). The difference between the two 
of them is that RIC uses doses of alkylating agents that cause a cytopenia that 
requires from stem cell support to resolve whereas the NM does not. The 
therapeutic approach is different from myeloablative conditioning, since it relies 
on the graft-versus-tumor effect, meaning that the donor’s immune system will 
attack the tumor cells recognizing them as non-self-cells and attack them. The 
doses in RIC are usually 30% lower than HDC (busulfan, melphalan, and 
Thiotepa are the most common alkylating agents in RIC). In NMC, low-dose 
combinations of fludarabine + cyclophosphamide + thymoglobulin, cladribine + 
cytarabine, or fludarabine + cytarabine + idarubicin have shown the best 
outcomes. TBI conditioning at lower radiation doses is also used in these 
cases.(47,48) 
 
     Figure 1.2.2. Therapeutic approximation to the different HSCT condition regimen.(42) 
After the transplant, the host must receive chronic immunosuppressive therapy to 
avoid graft-versus-host disease. This happens when the immune system of the donor 
recognizes the cells of the host as targets and attacks them. The balance between GVT 
effect and GVHD must be considered in RIC and NMC regimens. Modified grafts HSCT 
are being developed in rats to avoid GVHD while preserving GVT effect performing TBI 
and anti-thymocyte globulin.(49,50) 
The most common complication of HSCT is disease relapse, a lower life expectancy, 
and a higher incidence of long-term complication of different natures compared to 
disease-free population. Secondary cancers such as post-transplant lymphoproliferative 
disorders resulting of an Epstein-Barr virus infection, secondary myelodysplastic 
syndrome, acute myeloid leukemia (5-10% hosts), and other solid tumors. Organ-
specific impairments might arise due to chronic GVHD, TBI sequels, or long-term 
treatment with immunosuppressors like corticoids and calcineurin inhibitors. 
Furthermore, due to the immunosuppression, HSCT patients are susceptible of 
infections by opportunistic bacteria.(51)  
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Indirect effects in the quality-of-life of the hosts are the psychological effects. They 
often have difficulties reentering the laboral market with lower rates of job finding in the 
following five years after the intervention, and in their reintroduction in society, partly due 
to sexual dysfunction, fertility impairments, anxiety, depressive symptoms and negative 
body image, although it seems to be improving over the years.(52,53)  
 
3.2. Population pharmacokinetics 
During the 20th century, different approaches were developed to describe the 
Pharmacokinetic-Pharmacodynamic behavior of a drug in humans and predict its 
efficacy. Even though pharmacometrics started in 1920’s with Widmark, it gained 
recognition in the 1960’s decade. Pharmacometry aims to characterize, understand, and 
predict the pharmacokinetics and pharmacodynamics of a drug, quantify its uncertainty, 
and standardize the decision-making process in clinical practice.  
Nowadays, a pharmacometric assessment is crucial during the clinical studies, and 
has a great impact on its development. Initially, pharmacometry was intended to obtain 
information regarding the disposition of a drug in each individual (individual 
pharmacokinetics), but it was later replaced by the need to estimate population 
parameters and how they diverged into different subgroups. Hence, S. Beal and L. 
Sheiner, conceived the aforementioned Population Pharmacokinetics (POPPK). Both 
FDA (“Guidance for Industry: Population Pharmacokinetics”) and EMA (“Guideline on 
reporting the results of Population Pharmacokinetic analyses”) have developed 
standardized guidelines advising the possible situations where POPPK may be of 
service. It is considered highly advantageous in drugs with a narrow therapeutic window 
and/or targeting a very heterogeneous population.  
It can also be used in Phase I dose ranging studies where a small group is tested, 
or Phase II studies, where information is key in how the drug will be used in Phase III 
studies and a moderately higher number of subjects are used. Furthermore, a 
combination of Phase I and Phase II data may provide high-quality evidence of the drug 
on account of wide dose-range and number of patients of the resulting combined 
model.(54,55)There are two main approximations for the pharmacometrician to explore: 
— The Naïve Pooled Data approach treats all the observations as if it came from a 
single patient. It is an easy approach but drops a great deal of information by 
leaving the population variabilities unexplored and uncharacterized. Furthermore, 
it provides a poor estimation of parameters. Its use is limited in clinical practice 
since it does not account for physiological changes. 
— The Two-Stage approach uses traditional pharmacokinetics to estimate the basic 
parameters of the drug for each individual using non-linear regression technics. 
The second stage summarizes the mean, variance and covariance of the 
parameters and how they are affected by covariates. This method usually 
overestimates the residual error. The working unit is the patient and so there must 
be sufficient data of each individual to calculate the parameters. With the results 
and patient’s data, concentrations may be predicted using a Bayesian estimation. 
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— The Nonlinear Mixed Effect Modelling (NONMEM) approach uses the population 
as a whole, which makes it suitable for situations where the patient input is 
sparse, unbalanced and/or fragmentary. In just one step, this approach 
calculates the population pharmacokinetic parameters, its variance, and 
covariance while accounting for individual characteristics that may be used as 
covariates to a better explanation of the model. This approach requires the use 
of specific software, being NONMEM the gold-standard.(56) 
In the populational models using NONMEM software’s nomenclature, for each 
structural parameter, there is a fixed value expressed with the letter THETA (θ) that 
represents the Typical Value (TV) of the population. Depending on the specified basic 
model we might have different structural parameters. On the other hand, we have 
two random-effect values for each parameter: ETA (η) that accounts for Between 
Patient Variability (BPV) and Interoccasion Variability (IOV) and which variation is 
represented by OMEGA (ω2), and EPSILON (ε) that represents the unexplained 
difference between predicted and observed values and which variance is defined by 
SIGMA (σ2).(57) 
For BPV and IOV the variation can be explained by different random effects 
models each one describing the supposed behavior of it. The main models are: the 
additive error model that assumes the same magnitude of variability regardless of 
the value of the parameter (constant standard deviation); the Constant Coefficient 
Variation (CCV) maintains the same CV value making the standard deviation 
increase when the mean population value increase; the most used model is the 
Exponential model which assumes the variability follows a log-normal distribution. 
There are also error models for random variability that aim to explain its behavior. 
The main ones are: The Additive Variation; the Constant Coefficient Variation (CCV); 
the Additive plus CCV which combines the two previous models, so the Additive 
model dominates at low values whereas the CCV dominates at larger values; and 
Log-error model assumes a log-linear distribution of the residual values. (56,58) 
Figure 1.3.1. A) Additive error model. B) CCV error model. C) Additive + CCV error model.(56) 
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4. OBJECTIVES 
The main objectives of this final degree project are: 
1. Comprehend population pharmacokinetic models of drugs, especially in Narrow 
Therapeutic Index drugs (NTIs). This objective will be accomplished starting from 
basic pharmacokinetic knowledge acquired from academic formation.  
2. Acquire a comprehensive insight of NONMEM® software as a tool in Nonlinear 
Mixed Effects Models and its potential impact in the current gender gap in clinical 
trials.  
3. Development of a Population Pharmacokinetic Model of Busulfan employing data 
collected from the Catalan Oncology Institute (ICO) patients subjected to 
conditioning therapy for Hematopoietic Stem Cell Transplantation.  
4. Confirm the predictive performance of the resulting model with appropriate 
validation methods. 
5. MATERIALS AND METHODS 
5.1. Bibliographic methods 
For this project, we performed an exhaustive research employing articles and books 
extracted from the PubMed section of NCBI, and the CRAI (“Centre de Recursos per 
l’Aprenentatge i la Recerca”) searching tool “Recercador+” available for students of the 
University of Barcelona (UB). Due to the long period of time that busulfan has been in 
the market, there were few new publications regarding its pharmacokinetics. Information 
regarding gender inequality in clinical trials using the aforementioned tools was also 
gathered to assess its current situation in science. Books were obtained from the CRAI 
library or provided by the Unit of Biopharmacy and Pharmacokinetics of the Pharmacy 
and Food Science Faculty. 
The “Population Pharmacokinetics Studies” postgraduate course was taken in order 
to further understand the theoretic bases of the discipline and the coding language of the 
NONMEM. Furthermore, the assistance to several “R®” seminars was required to 
interpret NONMEM output and to execute the preliminary data analysis. 
5.2. Screening and analytical methods 
 Using the ICO’s Standard Operating Procedure (SOP) “Acondicionamiento para 
TPH” (PNT-TPH-004), the appropriate dosage of Busulfan and other concomitant drugs 
for the conditioning treatment in HSCT was applied to the 103 patients that were included 
in this project. All the subjects were about to receive an HSCT either autologous or 
heterologous, but the conditioning treatment varied depending on the base illness to be 
treated. 
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All patients received concomitant phenytoin 24 hours before starting Busulfan to 
avoid seizures, a common adverse event of this drug. Patients who used a conditioning 
treatment without Busulfan were not included in the project. Also, this model only used 
oral administration data and all patients dosed with intravenous busulfan were discarded 
from de database leaving 98 patients left to build the model. 
Two sample tubes with 3 mL of blood in EDTA of each patient were collected at time 
zero (before dosing) to be used as a blank, and at 1.5, 3, 4, and 6 hours posterior to the 
first dose. The date and hour, alongside the information of the patient, the dose, and the 
concomitant medication were introduced in the template available in SOP “Protocol de 
Monitorització del Busulfà (1ªDosis)”. Samples from the subsequent doses were 
obtained at times 2- and 6-hours post-administration according to the SOP “Protocol de 
Monitorització del Busulfà (Altres)”. Both templates are available in ANNEX 2. 
The samples were preserved in the fridge at 4ºC until they were sent to the Santa 
Creu i Sant Pau Hospital Biochemistry Laboratory to be analyzed with a HPLC validated 
method with a Limit of Quantification (LOQ) of 100 ng/mL. 
5.3. Pharmacokinetic modelling methods 
5.3.1. Excel database building 
The information used to build the database was obtained from the Pharmacy Service 
of the Catalan Oncology Institute. Dr. Carmen Muñoz Sanchez and Dr. Nuria Gonzalo 
Diego compiled data from 103 patient being administered with either oral or intravenous 
Busulfan conditioning before undergoing a Hematopoietic Stem Cell Transplant.  
The aim of the Excel database was providing understandable information for the 
pharmacokinetic analysis program NONMEM, which uses a specific coding. This step 
was key to obtain consistent data from NONMEM.  
We used in our table preserved names that NONMEM provides for certain 
measurements:  
— ID: subject identifier, all records of the subject must be continuous or NONMEM 
treats them as different subjects. 
— TIME: represents the moment in which an event occurs and must always be 
present, positive and increasing. This parameter may be substituted in plotting 
and analysis by Time After Dose(TAD). 
— AMT: this parameter represents the amount of drug given to the patient in a 
specific record. AMT must be zero when a DV value is present. 
— DV: this is the dependent value, which is concentration (ng/mL) in our case. This 
value must be zero when a dose (AMT) is given to the subject. DV values under 
the LOQ were hidden from the dataset. 
— MDV: the missing data value parameter is used to indicate the absence of a DV 
record value. MDV = 0 when there is a DV value, and MDV = 1 when its missing. 
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— EVID: this parameter refers to the type of record. EVID = 0 is used for observation 
events, EVID = 1 for dose events, EVID = 2 for other type of event records, and 
EVID = 3 and 4 is for reset of the conditions of the system. 
— CMT: compartment parameter indicates in which compartment is happening the 
record. In our case, CMT = 1 described oral dose records and CMT = 2 was IV 
doses or observational records. 
— OCC: occasion parameter is used to separate different curves observations in 
the same patient. 
ADDL and II were not included in our table because based on the protocol for plasma 
concentration sampling, we mostly had measurements of the first curve, punctual 
measurements to assess dose adjustments during the conditioning, and there were no 
dosing interval variations.  
Regarding the covariates (non-preserved parameters), we used shortened names 
because programs such as Xpose4 may misread the table with long headers. The 
covariates are grouped in two: 
— Continuous covariates:  
• AGE 
• WEIGHT 
• PCIA (Adjusted Ideal Body Weight) 
• HGT (Height) 
• AREA (Body Surface) 
— Categorical covariates: 
• GEND (Gender): where Man = 0, and Woman = 1. 
• FHEP (Altered Hepatic Function): where NO = 0, and YES = 1. 
Parameters that were considered as an alteration were: out-of-range 
AST, ALT, GGT, FA, and/or Bilirubin levels. 
• Assessing concomitant conditioning drugs was deemed of interest in 
order to search for pharmacokinetic interactions. Drugs were added as 
individual covariates and coded as NO = 0, and YES = 1: 
FLUD (Fludarabine) 
CICLO (Cyclophosphamide) 
TIMO (Thymoglobulin 
TIO (Thiotepa) 
• INDICATION: not all patients suffered from the same illness, but there 
was a mixture of oncological problems we intended to explore individually 
during our population PK model. There was a myriad of them, hence we 
created 6 generic groups under this covariate: 
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1. Lymphoblastic Acute Leukemia 
2. Myeloid Chronic Leukemia 
3. Myeloid Acute Leukemia 
4. Hodgkin Lymphoma 
5. Non-Hodgkin Lymphoma 
6. Multiple Myeloma / Waldenström Myeloma 
5.3.2. Data exploration 
Building a population PK model required an understanding and familiarization with 
the data. This was achieved using the statistical software R (v.3.5.2), specifically R 
package: Xpose4 (v.4.6.1). This software allowed us to analyze the patients as a group 
and portray its characteristics. It is also useful to see trends and identify outliers. We also 
generated exploratory histograms, dot plots, and scatterplots for covariates, that defined 
correlations between these, and helped us understand the results of the covariate model 
building in latter steps. 
5.3.3. Model Building 
The process of modelling was sequential. The initial step, once the data had been 
assessed, was writing the control file in a “.mod” text file with NONMEM coding language. 
The control file, also named NM-TRAN (NonMem TRANslator), is the framework that 
contains the commands we want NONMEM to perform, for instance calling the dataset, 
or executing the appropriate subroutines. The file is very sensitive to misspelling and 
additional characters that can disrupt the proper run of the desired model. The NM-TRAN 
was defined in a series of “Blocks”, always preceded by a “$” sign. The basic blocks are: 
1. $PROBLEM (also PROB or PRO) which contained the name of the file or its 
characteristics. When developing a model, hundreds of control files were crated 
with slight variations between them. Therefore, it was useful to specify the 
change, in less than 160 characters in a unique line, in this part of the control file. 
2. $INPUT allowed us to state the headers to NONMEM and recognizing them as 
either variable or covariate. This block had to be in a single row and each header 
was separated from the other with one blank space. NONMEM allows a 
maximum of 50 active variables per run. If our dataset had had more, we could 
have introduced them all, and then introduce “=DROP” in the variables that were 
not needed. There are reserved names, these are: ID, DATE, DAT1, DAT2, 
DAT3, TIME, DV, AMT, RATE, SS, II, ADDL, EVID, MDV, CMT, PCTM, CALL, 
CONT, L1, and L2. 
3. $DATA indicated to the program the name of the file we were using in the run. 
Typically, it also indicates where the file is located, but in our case, we indicated 
it to the program itself in the command window. Additionally, we used the 
“IGNORE=#” command to indicate that when a “#” sign was found in the dataset, 
it had to be ignored. We used this to hide the headers, outlier patients or 
observations. 
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4. $SUBROUTINES is a block dedicated to specifying the structure and desired 
parametrization. It states the number of compartments of the model with the 
ADVAN, and the parameters that were used in the subroutine. There are multiple 
possible combinations to explore with NONMEM. 
5. $PK contained the appropriate parameters required by the ADVAN/TRANS 
subroutine. This block contained different rows allowing a clearer expression of 
the code. For each parameter, we gave a THETA number to its typical value and, 
in the second row, we defined the behavior of its interindividual variability 
(additive variation, constant coefficient variation, or exponential variation).  
The predicted concentrations were produced in mg/mL. Since our data was set 
in other units (ng/mL), we used a correction factor “S2” of 1000 (S2=V/1000).  
When the covariate model is engaged with, we introduced them in this block next 
to the THETA row with IF-THEN structures for categorical covariates or 
multiplying THETA for a normalized parameter (parameter divided for its mean 
value). 
6. $ERROR defines the residual error (RE) specifications for the model in several 
rows. Using the statement “IPRED=F” we indicated that F is the Individual 
Predicted Concentrations values. The block also contains the parameters IRES 
(Individual Residuals) that were the observed concentration minus the IPRED, 
and the parameter IWRES (Individual Weighted Residuals) which was IPRED 
wheighted with a parameter. We equaled “W” to either 1 (for additive error), F (for 
Constant Coefficient of Variation error), or IPRED=LOG(F) plus W=1 (for log 
transformed additive error). 
7. $THETA was the block dedicated to set the initial estimate parameters of the 
THETAs. There were as many $THETA rows as parameters in $PK. The initial 
values were extracted from literature. They had to be written in brackets with or 
without upper and lower limits for said value. We lower-limited our parameters to 
zero. We also fixed some THETAs value such as the bioavailability (TVF) to 1 
since we did not include intravenous patients in the model and therefore, we 
could not have calculated it. 
8. $OMEGA was used to introduce the initial estimates for ETA variance (ω2). 
Generally, when there is a lack of information regarding its variability, we assume 
a 50% expressed as Coefficient of Variability. 
 𝐶𝑉 = √ω2 × 100   →    0.5 = √ω2  →    ω2 = 0.25 
9. $SIGMA was used to introduce the initial estimates for EPSILON variance (σ2). 
Generally, when there is a lack of information, we proceed as in $OMEGA block.  
𝐶𝑉 = √σ2 × 100     →    0.5 = √σ2   →     σ2 = 0.25 
10. $ESTIMATION was a single row block to state the estimation method. We used 
a First-Order Conditional Estimation (FOCE), which estimated population 
parameters and individual-specific parameters in a single step conditioning them 
during the process of minimization. 
Development of a Population Pharmacokinetic Model of Busulfan in HSCT Marc Reina Aibar 
 
- 14 - 
 
11. $COVARIANCE (also COV) indicated a further post-processing of data after the 
minimization process to calculate standard errors, the covariance matrices, the 
correlation matrices, and the inverse of variance-covariance matrices for each 
estimated parameter. 
12. $TABLE rows controlled the output, creating tables with detailed results of 
desired parameters in files separated from the “.lst” general result file. The name 
of this file was established in this row, and it’s recommended that it matches the 
name of the run to facilitate the check-out in further steps. We requested 4 
$TABLE for each of our runs: one for categorical covariates (catabxxx), one for 
continuous covariates (cotabxxx), one for parameters (patabxxx), and one for 
residual parameters along with TAD and IPRED (sdtabxxx). 
The building of a model dwelled in constructing a basic model and adding one 
change at a time. Two models with one change between them are denominated nested 
models. Each model had its own Objective Function Value (OFV), that was provided by 
NONMEM. Minus twice the logarithm of the difference between two nested models 
follows a ᵪ2 distribution. Therefore, we were able to establish numerical p values based 
on this distribution. An ΔOFV < - 3.84 equals to a p-value of 0.05, an ΔOFV < - 7.88 
equals to a p-value of 0.005, and an ΔOFV < -10.83 equals to a p-value of 0.001. Another 
sign of improvement is the reduction of the ETA variance (ω2) of at least 10%. 
The comparison of two non-nested models, for example one-compartment versus 
two-compartment models, must be performed with the Akaike Information Criteria which 
was calculated for the two models. The best model was the one with the lowest value. 
This method favors simple models with less variables (k). 
𝐴𝐼𝐶 = 2𝑘 − 2𝐿𝑛(𝑂𝐹𝑉) 
A number of control files to define the structural part of our model (base model) were 
written. This part consisted in determining which parameters suffer a significative 
interindividual variability reduction by decreasing the OFV at least -7.88. This part of the 
model optimization usually has great variations in the OFV, due to the great flexibility 
and poorness-of-fit of previous models. We established that at this level, the OFV 
parameter was enough to accept or dismiss a change in the model. 
Once the structural part had been selected, we began to apply the covariates to the 
model one at a time and check each Minimum Objective Function Value. In this 2nd step, 
called “Forward”, we accepted a change with a p-value<0.05 and a ΔETA1(%) or 
ETA2(%) of at least 10%. The acceptance criteria were less restrictive than the previous 
stage being that each significant covariate was re-challenged in the 3rd stage of the 
process called “Backwards”. The Backwards process eliminated the first covariate added 
to the final model, and that covariate was considered significant if the OFV worsened at 
least 10.83 points. This process is necessary because the adding covariates in a certain 
sequence does not provide the same results as another, even though the final OFV is 
the same, as a result of the flexibility of the structural initial model.  
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5.3.4. Model Validation 
The final model obtained after the Backwards process was asserted to ensure its 
predictive ability. There are two general kind of validations: external and internal. 
External validation was not performed during this process since data from other studies 
or subjects have not been acquired though it may be done in the future.  
We ran internal validation procedures that did not require previous segregation of 
subjects from the dataset, accounting that all subjects were introduced to build a better 
model. The two arrangements we used to challenge our model were: 
— Visual Predictive Check (VPC): an internal validation process that uses the 
characteristics of each patient to perform a given number of simulations for each 
observation using a determinate model. We executed one thousand simulations 
using the best fitting model.  
The program generated the simulated values using the ω2 and σ2 matrices 
applied to each subject observation but keeping the structural and covariate 
model parameters unaffected. The final control file had to be slightly changed to 
perform this process. Firstly, the initial estimates for the $THETA, $OMEGA, and 
$SIGMA block were substituted and fixed for the estimated values given by the 
output datafile of the final model. Secondly, the $ESTIMATION and $COV were 
replaced by the $SIMULATION block which contained the number of simulations 
(SUBP=1000) and a 7-figure number (SEED=1234567) which was the starting 
number for random sampling number generation. 
The results were exported to an output Excel compatible datafile with the median 
and confidence intervals (5th and 95th) of all simulations and the median and 
confidence intervals (5th and 95th) of all subject observations at each time after 
dose. The model was considered valid if the real values were within the 
confidence intervals and the median of the simulations. With Xpose4 (v.4.6.1) 
package in R (v.3.5.2) we performed a visual plot with these values.  
— Bootstrap: an internal validation process that digress from the previous one in 
the generation of datasets. Bootstrap created datasets called “subsets”, with the 
same number of subjects by randomly resampling patients from the original 
dataset and applying the model to them. The newly generated subsets might not 
have all the subjects from the original dataset and might have repeated subjects. 
The performance of the bootstrap procedure was obtained by generating one 
thousand subsets and obtaining the overall median and a 95th interval confidence 
(percentile 2.5th and 97.5th) of every parameter: OFV, THETAs(1-4), ETAs (1 and 
2), OMEGAs, and SIGMA. The median of the original dataset parameters must 
be enclosed by these intervals to be considered satisfactory. 
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6. RESULTS 
6.1. PRELIMINARY DATA EXPLORATION  
The retrospective chart included all subjects treated with Busulfan as a medullar 
depletion before an HSCT between 2012 to 2018. Data was collected from 103 patients, 
98 of which were used to build the pharmacokinetic model. 
The preliminary assessment of data begins with the demographic and biochemical 
characteristics of our patients, which are summarized in Table 5.1.1. 
Table 5.1.1. Summary of Median (Minimum, Maximum ) values of the target 
population.   
 N= number of patients 
A total of 523 plasma concentrations were obtained from  98 patients. Each patient 
was sampled according to the SOPs. The administered dose to a given subject was 
calculated based on its weight at reason of 1 mg/kg every 6 hours. Patients 4, 30 and 69 
received a dose of Acetaminophen, which has a described interaction with Busulfan. 
Other medications with possible interactions such as metronidazole, CYP3A4 inhibitors 
antifungals, and antipsychotics were checked.  
We observed the behavior of Busulfan with a Concentration (ng/mL) vs TAD (Time 
After Dose) plot displayed in Figure 5.1.1. 
 
 
Variable 
 
 
Units Median 
 
Range 
SEX (M/F) N 56/43 - 
AGE Years 52.02 20 - 69 
WEIGHT Kg 73.72 36 - 119 
PCIA (Adjusted Ideal Body Weight Kg 64.21 41.78 – 91.08 
HEIGHT m 1.67 1.46 – 1.92 
AREA m2 1.82 1.25 – 2.38 
GOOD HEPATIC FUNCTION 
(YES/NO) 
N 62/37 - 
ADDITIONAL 
IMMUNOSUPRESSION 
  - 
    FLUDARABINE N 90 - 
    CYCLOPHOSPHAMIDE N 
 
52 
- 
    TIMOGLOBULINE N 19 - 
    TIOTEPA N 2 - 
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Figure 5.1.1. Individual DV vs TAD plot during exploratory data analysis. 
During the preliminary exploration, the medium and range of the continuous 
covariates was examined, alongside their homogeneity by performing dot plots for each 
one. Our data provided a homogeneous dispersion, enhancing the accuracy of 
predictions of the model in high and low values of each covariate. The resulting dot plots 
are shown in the Figure 5.1.2. 
 
Figure 5.1.2. Dispersion of continuous covariates 
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In order to conclude the initial covariate checkout, we performed a scatterplot 
confronting each variable with the rest to determine correlations. When two covariates 
have correlation, they are not likely to enhance the model when applied together. The 
scatterplot is shown in Figure 5.1.3 and includes only AGE, WEIGHT, PCIA, HEIGHT 
and AREA. We expected correlation between anthropometric measurements, and the 
outcome further confirmed it. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.3. Scatterplot matrix of continuous covariates. 
Figure 5.1.4. Antropometric differences between gender. There is different median values for the represented covariates 
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6.2. MODEL DEVELOPEMENT 
6.2.1. Base model development 
The first step in PK modelling is finding the base model that best describes our data. 
We began with the simplest one-compartment extravascular model and evolved to 
models with higher complexity. To clearly represent the results of this stage of the 
process we standardized the NONMEM’s output in Tables. 
The decision to preserve a change in this step is, as previously stated, a reduction 
in the Objective Function Value of 7.879 which equals a  p value <0.005. The results of 
this process are displayed in tables 5.2.1 and 5.2.2 
 
Table 5.2.1. One-compartment base models. 
. 
  
 
RUN Nº 
 
 
CHANGE 
 
OFV 
 
ΔOFV 
 
CHANGE DECISION 
Run 101 PK model 
IIV 
RE 
One compartment 
None 
Additive 
 
6664.37 
 
- 
 
- 
Run 102 PK model 
IIV 
RE 
One compartment 
CL 
Additive 
 
6203.41 
 
-460.96 
 
ACCEPTED 
Run 103 PK model 
IIV 
RE 
One compartment 
Cl + V 
Additive 
 
6079.16 
 
-124.25 
 
ACCEPTED 
Run 104 PK model 
IIV 
RE 
One compartment 
CL + V 
Proportional 
 
5931.11 
 
-148.05 
 
ACCEPTED 
Run 105 PK model 
IIV 
RE 
One compartment 
CL + V + Ka 
Proportional 
 
5924.65 
 
-6.46 
 
DISCARDED 
Run 106 PK model 
IIV 
RE 
One compartment 
CL + V + TLAG 
Proportional 
 
ND 
 
- 
 
- 
Run 107 PK model 
IIV 
RE 
One compartment 
CL + V + TLAG 
lim=0 
Proportional 
 
5931.15 
 
+0.04 
 
DISCARDED 
Run 108 PK model 
IIV 
RE 
One compartment 
CL + V 
Additive–
Proportional 
 
6207.71 
 
+276.60 
 
DISCARDED 
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At first sight, run105 provided the lowest OFV (5924.65) but the application of IIV in 
Ka did not produce a significant reduction compared to run104 (5931.11). Therefore, 
run104 was our candidate among the one-compartment pool of models. 
Two-compartment model were attempted to obtain a better description of the 
distribution-elimination process. The results are shown in Table 5.2.2. 
Table 5.2.2. Two-compartment base models. 
 
Once the process had finished, we compared the best one-compartment model with 
the best two-compartment model using the AIC. Model 104 had an AIC = -13.37, a lower 
value than run 112 value AIC = -11.46. 
 
6.2.2. Covariate model development 
The influence of the covariates in the model was scrutinized in this step. Based on 
the acceptance limits stated in the methodology we accepted the covariates that had a 
significant positive effect explaining either clearance or distribution volume interindividual 
variability. 
 
 
 
 
 
 
 
RUN N.º 
 
 
CHANGE 
 
OFV 
 
ΔOFV 
 
CHANGE DECISION 
Run 109 PK model 
IIV 
RE 
Two compartments 
CL  
Additive 
 
7016.65 
 
- 
 
- 
Run 110 PK model 
IIV 
RE 
Two compartments 
CL + V 
Additive 
 
6616.39 
 
-400.26 
 
ACCEPTED 
Run 111 PK model 
IIV 
RE 
Two compartments 
CL + V 
Proportional 
 
6598.83 
 
-17.56 
 
ACCEPTED 
Run 112 PK model 
IIV 
RE 
Two compartments 
CL + V + Q 
Proportional 
 
6207.34 
 
-391.49 
 
ACCEPTED 
Run 113 PK model 
IIV 
RE 
Two compartments 
CL + V + Ka 
Proportional 
 
NULL 
 
- 
 
DISCARDED 
Run 114 PK model 
IIV 
RE 
Two compartments 
CL + V + Vss 
Proportional 
 
NULL 
 
- 
 
DISCARDED 
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Table 5.2.3. Covariates effects on clearance.  
 
 
 
 
 
RUN N.º 
 
COVARIATE CHANGE OFV 
 
ΔOFV 
(%) 
ETA 1 
 
ΔETA 
1 (%) 
 
CHANGE 
DECISION 
Run 104 BASE MODEL 5931.11 - 0.104 - - 
Run 115 CL WEIGHT 5917.01 -14.10 0.0889 -14.51 ACCEPTED 
Run 116 CL PCIA exp θ 5914.62 -16.49 0.0869 -16.44 ACCEPTED 
Run 116(1) CL PCIA  5914.46 -17.65 0.0856 -17.69 ACCEPTED 
Run 117 CL HGT 5923.71 -7.4’ 0.0954 -8.30 DISCARDED 
Run 118 CL AREA 5914.56 -16.55 0.0864 -16.90 ACCEPTED 
Run 119 CL AGE 5984.74 +53.62 0.186 +78.84 DISCARDED 
Run 125 CL GEND 5920.00 -11.11 0.0919 -11.63 ACCEPTED 
Run 126 CL 
GOOD 
HEPATIC 
FUNCTION 
5929.31 -1.80 0.102 1.92 DISCARDED 
Run 127 CL FLUDARABINE 5930.12 -0.99 0.102 1.92 DISCARDED 
Run 128 CL 
 
CYCLO 
 
5929.49 -1.62 0.102 1.92 DISCARDED 
Run 129 CL TYMOGLOBULIN 5926.19 -4.92 0.0981 5.67 DISCARDED 
Run 130 CL THIOTEPA 5931.09 0 0.104 0 DISCARDED 
Run 131 CL INDICATION 5928.88 -1.23 0.101 2.88 DISCARDED 
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Table 5.2.4. Covariates effects on distribution volume 
  
 
RUN N.º 
 
 
COVARIATE 
CHANGE 
 
OFV 
 
ΔOFV 
(%) 
 
ETA 2 
 
ΔETA 2 
(%) 
 
CHANGE 
DECISION 
Run 104 BASE MODEL 5931.11 - 
 
0.0597 
- - 
Run 120 V WEIGHT 5909.46 -21.65 0.0441 -26.13 ACCEPTED 
Run 121 V PCIA exp θ 5900.96 -30.15 0.0381 -35.18 ACCEPTED 
Run 121(1) V PCIA  5900.96 -30.53 0.0386 -35.34 ACCEPTED 
Run 122 V HGT 5916.64 -14.47 0.0481 -19.43 DISCARDED 
Run 123 V AREA 5903.14 -27.97 0.0395 -33.83 ACCEPTED 
Run 124 V AGE 6010.73 +79.62 0.1690 +183.08 DISCARDED 
Run 132 V GEND 5919.22 -11.89 0.0505 -15.41 ACCEPTED 
Run 133 V 
GOOD 
HEPATIC 
FUNCTION 
5930.99 -0.12 0.0596 -0.16 DISCARDED 
Run 134 V FLUDARABINE 5930.39 -0.724 0.0590 -1.17 DISCARDED 
Run 135 V 
CYCLO 
 
5931.08 -0.03 0.0598 +0.16 DISCARDED 
Run 136 V TYMOGLOBULIN 5930.95 -0.16 0.0597 0 DISCARDED 
Run 137 V THIOTEPA 5930.01 -1.10 0.0594 0.50 DISCARDED 
Run 138 V INDICATION 5920.49 -10.62 0.0514 -13.90 ACCEPTED 
Run 142 V 
INDICATION 
HODGKIN 
LYMPHOMA 
 
5921.87 -9.24 0.0528 -11.56 ACCEPTED 
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The BPV of the clearance and distribution volume of busulfan was better explained 
by the PCIA, the AREA and the GENDER. Patients with Hodgkin Lymphoma showed a 
significant difference in volume compared with the rest of indications. 
The building of multivariate models was executes and the results were exposed in 
Table 5.2.5. and Table 5.2.6. 
Table 5.2.5. Mixed covariate effects on clearance models. 
 
Table 5.2.5. Mixed covariate effects on distribution volume models. 
  
PCIA and AREA were the covariates that showed a better fit for the model. When 
tested univariately they provided a similar reduction of the objective function value, but 
together worsened the model. To finalize the covariate model building, all significant 
covariates were tested multivariately to build the final model. The results are exposed in 
Table 5.2.6. 
 
 
 
RUN N.º 
COVARIATE 
CHANGE 
OFV ΔOFV ETA 1 
 
ΔETA 1 
(%) 
CHANGE 
DECISION 
Run 145 CL GEND + PCIA 5914.50 -0.04 0.0868 +1.40 DISCARDED 
Run 146 CL GEND + AREA 5911.71 -2.85 0.0868 +0.46 DISCARDED 
Run 148 CL PCIA + AREA 5930.82 +16.36 0.104 +21.49 DISCARDED 
RUN N.º 
COVARIATE 
CHANGE 
OFV ΔOFV ETA 2 
 
ΔETA 2 
(%) 
CHANGE 
DECISION 
Run 149 V GEND + PCIA 5900.30 -0.66 0.0379 -1.81 DISCARDED 
Run 151 V GEND + AREA 5900.41 -2.73 0.0381 -1.29 DISCARDED 
Run 152 V LH + PCIA 5893.70 -7.26 0.0348 -9.84 ACCEPTED* 
Run 154 V LH + AREA 5896.03 -7.11 0.0357 -9.62 ACCEPTED* 
Run 155 V PCIA + AREA 5917.69 +14.55 0.0514 +30.12 DISCARDED 
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Table 5.2.6. Mixed effects on clearance plus distribution volume models. 
 
There was little difference between AREA and PCIA when applied in the model. It 
was decided to keep PCIA as our covariate. A correlation of ETAs was suggested by the 
exploration of the final model. However further analysis determined a poor correlation 
between ETA 1 and ETA2 despite the graphic scatterplot trend line indications. 
 
 
 
 
 
 
 
 
 
The resulting model, Run158, was the best fit. Its characteristics are shown in table 
5.2.7. 
Table 5.2.7. Forward best-fitting model results. 
 
 
RUN N.º 
 
 
COVARIATE CHANGE 
 
OFV 
 
ΔOFV 
 
CHANGE 
DECISION 
Run 156 
CL PCIA 
5876.02 -17.68 ACCEPTED 
V LH + PCIA 
Run 157 
CL AREA 
5876.41 -17.29 ACCEPTED 
V LH + PCIA 
Run 158 
CL PCIA 
5855.66 
 
vs. Run 142 
 
-38.04  
ACCEPTED V LH + PCIA 
 
 
vs. Run 156 
 
-20.36 
 
ETA1 
ETA2 
BLOCKED 
Figure 5.2.1. Scatterplot Matrix of ETAs. r2=0.544. 
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With this model, we ended the Forward process of model selection. Due to the 
model’s flexibility, adding covariates in a predefined  sequence may be different than 
another and for this reason we had to do a “Backwards” process which consisted in 
deconstructing the model eliminating the first covariate introduced in the final model and 
to observe if an increase (worsening) higher than 10 points in the OFV was induced. This 
would mean that such covariate has at least p<0.001 statistical significance. 
Table 5.2.8. Backward elimination process results. 
 
The results obtained in the backward process showed that separating patients with 
Hodgkin Lymphoma from the others in the model was not significant enough and 
therefore it was discarded from the model. 
The final model is a one-compartment model with two non-correlated ETAs, one in 
Clearance and one in Distribution Volume, both affected by PCIA covariate. With this, 
we finalized the model enhancement and proceeded to the next step. 
The Typical Values of the THETAs, and ETAs is shown in the table 5.2.9. 
Table 5.2.9. Typical Values of PK parameters in the definitive populational model. 
 
 
 
RUN N.º 
 
COVARIATE CHANGE OFV ΔOFV 
CHANGE 
DECISION 
Run 159 
CL PCIA 
5864.39 +8.63 
NOT 
SIGNIFICANT 
V PCIA 
ETA1 
ETA2 
BLOCKED 
Run 160 
CL - 
5879.72 
 
 
+24.06 
 
 
SIGNIFICANT 
V LH + PCIA 
ETA1 
ETA2 
BLOCKED 
Run 161 
CL PCIA 
5895.46 
  
+39.8 
 
SIGNIFICANT 
V LH 
ETA1 
ETA2 
BLOCKED 
Run 162 F Ka (h-1) CL/F (L/h) Vd/F (L) 
Value FIXED = 1 1.47 11.0 42.7 
ETA - - 0.0895 0.0394 
ETA correlation - - ω2,12=0.0322 / r2=0.544 
CV (%) of IIV   29.9 19.85 
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6.2.3. Internal Model Validation 
Results of the two internal validation methods (prediction visual predictive check and 
bootstrap) are shown in Figure 5.5.2 and Table 5.2.11 respectively.  
 
Figure 5.2.2. Time After Dose vs Observations of Simulated and Real populations. Pink areas enact as the median 
values, and the blue areas represent the 5th and 95th percentiles values of the simulations. The red lines embody 
the results of the observed real concentrations of the original population, the median is the continuous line and the 
dashed lines are the 5th and 95th percentiles. 
 Table 5.2.11. Bootstrap results compared to original population PK parameters. 
  
 
original sample 2.50% 97.50% % difference 
OFV 5860.51 5857.06 5552.04 6194.43 0.06 
THETA(1)→ F 1 1 1 1 0 (Fixed) 
THETA(2)→ Ka 1.467 1.451 1.184 1.839 1.08 
THETA(3)→ CL/F 10.982 10.976 10.395 11.584 0.05 
THETA(4)→ V/F 42.697 42.714 39.716 45.686 -0.04 
OMEGA(1,1) 0.0882 0.0883 0.0597 0.1235 -0.10 
OMEGA(2,1) 0.0319 0.0313 0.0117 0.0566 1.66 
OMEGA(2,2) 0.0386 0.0387 0.0230 0.0574 -0.10 
SIGMA(1,1) 0.0291 0.0293 0.0218 0.0361 -0.73 
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7. DISCUSSION 
The main objective of creating and developing a functional populational 
pharmacokinetic model has been accomplished throughout the 1st semester of 2019 as 
shown in the Results. For this purpose, knowledge of Nonlinear Mixed Effects Models 
and in NONMEM® software coding language was acquired. 
A total of 98 patients were included in the current analysis, with 523 plasma 
concentrations values analyzed and 363 doses administered. Demographic 
characteristics of the studied population showed a proper balance between genders, 
close to 50% with a slightly predominance of male in the population. A wide range of 
variation was observed for ages and anthropometric covariates (Figure 5.1.2). There was 
a significant number of patients (62 out of 98) with some alteration of the hepatic function. 
The liver plays a major role in the metabolism of busulfan, so it was a variable that had 
to be taken in consideration. All patients took at least one concomitant medication 
alongside busulfan. Only two patients took Thiotepa concomitantly. Although no 
interaction had been described between Thiotepa and Busulfan, this co-medication was 
tested as covariate on Bulsulfan clearance and neither statistical nor clinical influence 
was found. Therefore, this was deemed irrelevant.  
The pharmacokinetics of Busulfan was best described by a one-compartment model 
with first order absorption and elimination processes. This was in agreement with 
previous reported models developed after either oral or intravenous administration of 
Busulfan.(24,27,29–31,59) Only McCune J. et al., and Kawazoe A. et al. described the 
pharmacokinetics of busulfan with a two-compartment model. This discrepancy may be 
explained by the fact that these authors modelled intravenous data and a more intensive 
sampling schedule around the distribution phase was achieved. 
The final model provided the pharmacokinetic parameter values normalized by 
bioavailability (F), due to the lack of intravenous data in the modelling process. Clearance 
was estimated as 11.0 L/h, the distribution volume was 42.7 L, the half-life was 2.69 h, 
the apparent elimination rate constant (Ke) was 0.257 h-1, and the absorption rate 
constant was 1.47 h-1. These results agreed with those of the available literature, also 
developed form oral data, that reported a clearance (CL/F) around 12 L/h, and 
distribution volume (V/F) of 46 L.(24,27,29–31,59) Actually, according to McCune et al 
and Kawazoe et al, after its intravenous administrations busulfan showed a two-
exponential pharmacokinetic behavior with two disposition phases.(23,26) Therefore, 
once in the body Busulfan distributes from the central compartment to the peripheral 
according to its lipophilic nature. Unfortunately, this behavior could not be characterized 
with our model, but  the achieved model allowed a robust estimation of the plasma 
clearance. 
Regarding to the absorption rate constant of our model  (1.47 h-1 ), it was different 
from other previous studies (2.9 – 4.0 h-1).(29,31)There is a significant disagreement 
between the absorption rate constant, presenting a large variability between the 
reviewed models (CV = 15%), as well as in the clinical assays (CV = 45.9%). These 
differences could be due to the different sampling schedules applied during the 
absorption phase in these studies.    
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The interindividual variability could be included in Clearance and Volume with 
resulting values of 29.9 % and 19.8 % respectively. The only covariate identified as 
statistically significant was Adjusted Ideal Body Weight (PCIA) which reduced the OFV 
in 17.65 units (p<0.001) and led to a reduction of the BPV  in clearance of 17.69%. When 
tested in  distribution Volume, PCIA further decreased the OFV in 30.53 units (p<0.001) 
and its BPV a 35.34%. This was in agreement with other authors who also found a 
significant role of  anthropometric covariates such as Total Body Weight, Body Surface 
Area, Adjusted Ideal Body Weight, Fat Free Mass and/or Actual Body Weight on 
clearance, on distribution volume, or  both. Other studies also found Sex, Age, and ALT 
values as significant covariates. (23,24,61–64,25–31,60) 
The effect of gender was not perceived so clearly in our model. Although during the 
“Forward” process, GENDER (Sex) was statistically significant, it could not be retained 
in the model combined with anthropometric covariates. This fact does not deny the 
differences between man and women, because , actually, these differences are 
accounted by differences in PCIA values  in the model. 
The variable “Type of Indication” was tested as a covariate (especially those with 
Hodgkin Lymphoma in front of the other indications) and it was also found significant 
during the forward inclusion. But, no significant increase in the OFV was observed during 
the backwards elimination so it had to be removed from the model. It is worth mentioning 
the study of Hadjibabaie M. et.al. which described the effect of the targeted disease on 
the  Clearance of Busulfan. Unlike the aforementioned author, we only observed a trend 
for the influence of this covariate on the distribution Volume. 
The predictive capability of the model was confirmed by the Prediction Corrected 
Visual Predictive Check. According to Figure 5.2.2. The comparison of distributions of 
observed and simulated data suggested that the 50%, 5% and 95% percentiles of the 
observed data were within the 95% prediction intervals of the corresponding percentiles 
of the simulated data. There was a slight underestimation of the mean concentration 
value around 2 hours after administration. 
The stability of the model and precision of the parameter estimates were confirmed 
by the bootstrap methods with relative deviations between the population values and the 
mean values estimated by this method lower than 1.5% in all the cases. Moreover, the 
populational values were within the 95% confidence interval given by bootstrap. 
 An external validation should be carried out to further confirm the predictive power 
of the model before its application to the clinical practice as a support tool for dose 
calculations in the target population. 
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8. CONCLUSIONS 
Through the attendance to several lessons about population pharmacokinetics we 
gained sufficient insight to start developing our project. By means of a review of 
preexisting literature, we were able to comprehend the actual importance and 
applicability of POPPK models in the clinical practice, especially as a support tool during 
therapeutic drug monitoring of drugs with high interindividual variability and narrow 
therapeutic index. Moreover, this approach allows to overcome the limitations associated 
with the routine clinical practice when a low number of samples per patient is available.  
Among the different population analysis approaches, we focused on the non-linear 
mixed effects models. Despite its complexity, this methodology is highly powerful due to 
its great descriptive and predictive capability. Furthermore, the use of this approximation 
is a gender-friendly tool that allows the pharmacometrician to account for differences 
between man and woman, whether directly or indirectly through anthropometric 
measurements. 
The PK parameters of the final model were similar to those of previously reported 
models, between patient variability associated with parameters and residual errors 
associated with concentrations also presented a low variance. All the population 
pharmacokinetic parameters estimated were physiologically meaningful and the 
estimated interindividual and residual variabilities were acceptable. Furthermore, 
goodness-of-fit plots showed the descriptive capability of the model and the two applied 
internal validation techniques showed its predictive capability. 
In the second semester of 2019, the model will be translated to the Catalan Oncology 
Institute (ICO) and used to predict concentrations based on the specific anthropometric 
measurements of new patients subjected to HSCT (external population). From the 
collected data from several new patients an external validation will be performed to  
confirm its predictive capability and to evaluate its potential use as a support tool to either 
calculate the initial doses or if required for dose tailoring during the therapeutic drug 
monitoring .  
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ANNEX I: GOODNESS-OF-FIT COMPARATIVE 
EVALUATION OF DEVELOPED MODELS 
INITIAL MODEL (Run 101) 
   Figure A.1. Population Predicted Concentrations and Individual Predicted Concentrations vs Observed Concentrations 
 
   Figure A.2. Absolute value of Individual Weighted Residuals vs Population Predicted Concentrations. 
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   Figure A.3. Conditional Weighted Residuals versus Time After Dose. 
 
The Figure A.1 shows an underestimation of the predictive values respecting the 
observations at the lower values, whereas an overestimation can be seen in the higher 
values. The errors of the model have to be corrected in the following steps of the process. 
This model has yet to explain the Between Patient Variability and the effects of the 
covariates that remain uncharacterized as a residual error. 
The Figure A.2 shows a great IWRES (Individual Weighted RESidual), a 
representation of the unexplained errors between the predictions and the observations. 
This model shows a poor performance explaining the residual errors, giving a high 
absolute value of IWRES along the predicted values. 
The Figure A.2 shows a dispersion of CWRES (Conditional Weighted RESiduals). 
The range of dispersion is from 6 to -4, with a central tendency around zero. The range 
is wider than desired and have to be narrowed to accept the model. 
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BASIC MODEL (Run 104) 
 
Figure B.1. Population Predicted Concentrations and Individual Predicted Concentrations vs Observed Concentrations 
 
Figure B.2. Absolute value of Individual Weighted Residuals vs Population Predicted Concentrations. 
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Figure B.3. Conditional Weighted Residuals versus Time After Dose. 
 
Figure B.1 representing the fit of the model to the real observations, seems to have 
improved the Population predictions vs Observations, although the underestimation at 
low values and overestimation at high values persists. On the other hand, the Individual 
predictions vs Observations show a great enhancement on the model performance with 
an almost perfect fit. IPRED vs OBS is mainly affected by Between Patient Variability 
(BPV), whereas PPRED vs OBS is affected by BPV and the residual error. That explains 
why there is such a good fit of the first but not the second. The development of the basic 
model aims to explain BPV, that is now out of what was the residual error in Figure A.1. 
Figure B.2 shows a great reduction of IWRES values along the PPRED values since 
the BPV has been explained. We changed from an absolute value of IWRES of hundreds 
to decimal values. The next step was to further characterize the residual error using the 
covariate.  
Figure B.3. shows a narrower dispersion of CWRES over TAD, ranging from 4 to -4 
with a central tendency line at zero.  
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FINAL MODEL (Run 162) 
 
Figure C.1. Population Predicted Concentrations and Individual Predicted Concentrations vs Observed Concentrations 
Figure C.2. Absolute value of Individual Weighted Residuals vs Population Predicted Concentrations. 
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Figure A.3. Conditional Weighted Residuals versus Time After Dose.  
 
Figure C.1 represents the PPRED vs OBS and IPRED vs OBS plots of the best 
model, once the covariates have been testes and properly combined to characterize the 
residual values. The overestimation at higher values has been corrected and a light 
underestimation persist al lower values, which it’s not expected to have relevance in the 
performance of the model, since values that low usually are not of clinical relevance. 
Figure C.2 shows little variation of absolute IWRES value, but the dispersion of the 
dots has been reduced and grouped. This plot represents the residuals that were not 
explained by the final model. 
Figure C.3 representing the CWRES vs TAD shows a narrow range mostly between 
3 and -3, but mostly between 2 and -2, with a tendency at zero. Punctual CWRES values 
lay outside the 3,-3 range but it is still acceptable. 
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ANNEX II: SOPs FOR PLASMA SAMPLING 
 
 
MONITORITZACIÓ BUSULFÀ ENDOVENOSA PROTOCOL Al·loTIR 
Full Recollida de Dades d’Extracció 
Servei de Farmàcia - Servei d’Hematologia Clínica 
 
Nom Pacient:  Pes (kg):  S.C (m2):  
Història Clínica:  Alçada (cm):  Edat (anys):  
Identificació Hospital:  
Busulfà EV Infusió 2hores 
(0,8 mg/kg/6 h)  10 Dosis 
Dosi Total  
Administrada  
Data Inici  
(dd/mm/aa) 
Hora Inici Infusió 
(hh:mm) 
Hora Finalització  Infusió 
(hh:mm) 
    
 
Extraccions de Sang en Tubs EDTA – Utilitzar una Via Perifèrica 
Volum Mínim 2mL/Tub - Consevar en NEVERA!!! 
Registrar Hora d’Extracció en els Tubs !! Extreure 2 Tubs per Mostra 
Enviar Mostres al Laboratori Bioquímica – Hospital Santa Creu i Sant Pau 
Nº Mostra Hora Teòrica d’Extracció Data Real d’Extracció (dd/mm/aa) Hora Real d’Extracció (hh:mm) 
1 Pre-Dosi (Blanc)   
2 1,5 Hores Post-Inici Infusió   
3 3 Hores Post-Inici Infusió   
4 4 Hores Post-Inici Infusió   
5 6 Hores Post-Inici Infusió   
 
Medicació Concomitant Destacable: 
Fàrmac Posologia Via d’Administració 
   
   
   
 
Alteracions Funcionals Destacables/Altres Observacions: 
 
 
Nom:                                                                                           Signatura:                                  Data: 
 
Consultar qualsevol dubte amb el Servei de Farmàcia de l’Hospital Duran i Reynals. Institut Català d’Oncologia. 
Tel: 93-260-78-08 
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MONITORITZACIÓ BUSULFÀ ORAL-NIVELLS COMPROVACIÓ 
Després de la Cinquena dosi de Busulfà Administrada 
Full Recollida de Dades d’Extracció 
Servei de Farmàcia-Servei d’Hematologia Clínica 
 
Nom Pacient:  Pes (kg):  S.C (m2):  
Història Clínica:  Alçada (cm):  Edat (anys):  
Identificació Hospital:  
 
Busulfà Oral: 
Dosi Administrada (mg) Data Inici (dd/mm/aa) Hora d’Administració (hh:mm) 
   
 
Extraccions de Sang en Tubs EDTA - Volum Mínim 2mL/Tub - Conservar en NEVERA!!! 
Registrar Hora d’Extracció en els Tubs !! Extreure 2 Tubs per Mostra 
Enviar Mostres al Servei de Bioquímica - Hospital de Santa Creu i Sant Pau 
Nº Mostra Hora Teòrica d’Extracció Data Real d’Extracció (dd/mm/aa) Hora Real d’Extracció (hh:mm) 
1 2 Hores Post-Administració   
2 6 Hores Post-Administració   
 
Medicació Concomitant Destacable: 
Fàrmac Posologia Via d’Administració 
   
   
   
   
   
   
   
 
Alteracions Funcionals Destacables/Altres Observacions: 
 
 
 
 
 
 
 
 
Nom:                                                                                           Signatura:                                  Data: 
 
Consultar qualsevol dubte amb el Servei de Farmàcia de l’Hospital Duran i Reynals. Institut Català d’Oncologia. 
Tel: 93-260-78-08 
 
